少突胶质细胞瘤的临床特征与总生存预后列线图:基于SEER人群的分析
该研究基于SEER数据库1975—2016年诊断的4568例少突胶质细胞瘤患者,分析人口学、肿瘤与治疗因素与总生存的关系,并构建预测5年和10年生存概率的列线图。多因素分析显示放疗、年龄、肿瘤部位、总结分期和手术方式在两个分级队列中均与生存独立相关,列线图C指数为0.738(95%CI 0.718-0.757),校准曲线显示预测与实际观察吻合良好。
要点
- 列线图C指数0.738(95%CI 0.718-0.757),可用于预测5年和10年总生存概率。
- 放疗、年龄、肿瘤部位、总结分期和手术方式在II级与III级中均与生存独立相关。
- II级与III级少突胶质细胞瘤末次随访时平均生存时间分别为74个月和39个月。
核心结论
- 研究构建了首个用于预测少突胶质细胞瘤患者总生存的列线图,有助于临床医生较准确预测预后并指导后续治疗。
研究设计与样本
- 回顾性队列研究,数据来源于SEER数据库,纳入1975—2016年诊断的少突胶质细胞瘤病例,数据清洗后共4568例。
- 采用单因素和多因素分析评估年龄、性别、种族、保险、诊断年份、婚姻状态、肿瘤部位、肿瘤大小、总结分期、手术方式及放化疗与总生存的关系。
- 构建并验证预测5年和10年生存概率的列线图,以C指数和校准曲线评价。
- 按II级和III级少突胶质细胞瘤分队列进行多因素分析。
主要发现
- 末次随访时,II级和III级少突胶质细胞瘤的平均生存时间分别为74个月和39个月。
- 多因素分析中,放疗、年龄、肿瘤部位、总结分期和手术方式在两个分级队列中均与生存独立相关。
- II级少突胶质细胞瘤中,种族和放疗与生存独立相关;III级中,性别和化疗与生存独立相关。
- 列线图C指数为0.738(95%CI 0.718-0.757)。
- 5年和10年生存率的校准曲线显示列线图预测与实际观察吻合良好。
关键数值与推荐
- 列线图预测5年和10年生存概率,C指数0.738(95%CI 0.718-0.757)。
- II级少突胶质细胞瘤平均生存时间74个月,III级为39个月。
- 纳入分析的少突胶质细胞瘤患者共4568例,诊断年份为1975—2016年。
临床怎么用
- 可将列线图用于少突胶质细胞瘤患者总生存预测,辅助评估5年和10年生存概率。
- 分析结果提示放疗、年龄、肿瘤部位、总结分期和手术方式与两个分级队列的生存独立相关,可作为预后评估参考。
- II级患者中需关注种族和放疗因素,III级患者中需关注性别和化疗因素。
局限性
- 原文摘要未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Oligodendroglioma is a rare primary malignant brain tumor that has highly variable clinical outcomes. The aim of this study was to investigate demographics, outcomes, and prognostic factors of all oligodendroglioma cases from the Surveillance, Epidemiology, and End Results database to build a clinical prognosis model to predict survival time of patients with oligodendroglioma. METHODS: Cases diagnosed between 1975 and 2016 were selected from the Surveillance, Epidemiology, and End Results database. Age, sex, race, insurance, year of diagnosis, marital status, tumor location, tumor size, summary stage, surgery method, and use of radiotherapy and chemotherapy were evaluated with respect to overall survival by univariate and multivariate analysis. A nomogram predicting 5- and 10-year survival probability for oligodendroglioma was constructed and validated. RESULTS: After data cleaning, 4568 patients with oligodendroglioma were included. At the time of last follow-up, mean survival times among grade II and grade III oligodendrogliomas were 74 and 39 months, respectively. In multivariate analysis, radiotherapy, age, tumor site, summary stage, and surgery demonstrated independent associations with survival in both cohorts. Race and radiotherapy demonstrated independent associations with survival in grade II oligodendroglioma. Sex and chemotherapy demonstrated independent associations with survival in grade III oligodendroglioma. Independent factors in either cohort were selected to build a clinical nomogram. The C-index for the nomogram was 0.738 (95% confidence interval 0.718-0.757). The calibration curves of 5- and 10-year survival rates showed good agreement between the nomogram predictions and actual observations. CONCLUSIONS: This study was the first to develop a nomogram for predicting overall survival of patients with oligodendroglioma to help clinicians predict patient prognosis accurately and conduct further treatment.
引用
- Cao L, Rong P, Zhu G, et al. Clinical Characteristics and Overall Survival Prognostic Nomogram for Oligodendroglioma: A Surveillance, Epidemiology, and End Results Population-Based Analysis. World Neurosurg. 2021. PMID: 33964496. doi:10.1016/j.wneu.2021.04.122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。